First-in-human study with novel antisense oligonucleotide proves promising



First in Human Study with Novel Antisense Oligonucleotide
Credit: Mary Ann Liebert, Inc., publishers

A single intravenous dose of MRG-110, an anti-microRNA drug, considerably lowered miR-92a ranges within the blood of wholesome people. Inhibition of miR-92a has proven useful results in animal fashions, together with improved vascularization after myocardial infarction, and accelerated wound therapeutic, in response to the peer-reviewed journal Nucleic Acid Therapeutics.

“Based on documented, promising therapeutic potential, locked nucleic acid (LNA)-based anti-miR-92a was further developed and tested in a first in human study,” stated Stefanie Dimmeler, Ph.D., Goethe University, Frankfurt, Germany and coauthors. “MRG-110 caused de-repression of gene targets in human peripheral blood cells.”

“This is an important randomized, double-blind, placebo-controlled, dose-escalating study translating previous work on systemically delivered LNA-modified anti-miR oligonucleotide compounds to efficiently lower miR-92a levels in human peripheral blood,” says Executive Editor Graham C. Parker, Ph.D., The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children’s Hospital of Michigan, Detroit, MI.

New aptamer-based approach delivers microRNA therapeutic that targets cancer / cardiovascular disease

More info:
Wesley Tyler Abplanalp et al, Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study, Nucleic Acid Therapeutics (2020). DOI: 10.1089/nat.2020.0871

First-in-human study with novel antisense oligonucleotide proves promising (2020, August 12)
retrieved 12 August 2020

This doc is topic to copyright. Apart from any truthful dealing for the aim of personal study or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.


Source link

Leave a Reply